Skip to main content
. 2021 Apr 1;21:146. doi: 10.1186/s12876-021-01734-4

Fig. 5.

Fig. 5

Development of RS based on the 9 ARGs signature of patients with GC in TCGA and GEO. a, b The RS distribution, vital status of patients and heatmap of the 9 ARGs expression profiles between high risk group and low risk group in training or validation group. c, e Kaplan–Meier analysis of the prognostic model in TCGA or GEO datasets. d, f Time-dependent ROC analysis showing the optimal AUC of the gene signature in the two cohorts